Nectar Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 532649 | NSE: NECLIFE | Pharmaceuticals & Drugs | Small Cap

Nectar Lifesciences Share Price

30.25 0.20 0.67%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Nectar Lifesciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Nectar Lifesciences stock performance -

mw4me loader
P/E Ratio (SA):
69.14
Market Cap:
675.3 Cr.
52-wk low:
14.4
52-wk high:
45.7

Is Nectar Lifesciences Ltd an attractive stock to invest in?

1. Is Nectar Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company.

2. Is Nectar Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Nectar Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Nectar Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Nectar Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nectar Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 9%8.4%7.4%7.2%6.8%7.5%6%1.2%3.8%0.3%-
Value Creation
Index
-0.4-0.4-0.5-0.5-0.5-0.5-0.6-0.9-0.7-1.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,6381,6441,6761,6431,8762,7852,3631,5421,6681,5241,632
Sales YoY Gr.-0.3%2%-2%14.1%48.5%-15.2%-34.8%8.2%-8.7%-
Adj EPS 2.832.42.42.32.11.3-2.50.8-2.30.4
YoY Gr.-6.5%-17.6%-0.4%-3.7%-9%-37.3%-285.7%NA-370.2%-
BVPS (₹) 41.341.142.644.947.249.350.647.348.547.547.7
Adj Net
Profit
62.166.254.454.352.247.529.9-55.418.7-50.810
Cash Flow from Ops. 25514416919965.123928621.395133-
Debt/CF from Ops. 3.46.45.74.414.73.82.742.49.15.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -0.8%-4.1%-13.6%-8.7%
Adj EPS -197.8%-199.5%-219.5%-370.2%
BVPS1.6%0.1%-2.1%-2%
Share Price 2.1% 12.1% 17.4% 101.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
6.975.75.55.14.42.7-51.7-4.70.9
Op. Profit
Mgn %
17.616.214.313.612.69.59.26.69.53.67.6
Net Profit
Mgn %
3.843.33.32.81.71.3-3.61.1-3.30.6
Debt to
Equity
0.9110.90.90.80.70.90.80.7-
Working Cap
Days
270285298324292206240330288310140
Cash Conv.
Cycle
12513414215313310411513210812638

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 0.90%

Debt to equity has declined versus last 3 years average to 0.71

Sales growth has been subdued in last 3 years -13.61%

Net Profit has been subdued in last 3 years -219.51%

Sales growth is not so good in last 4 quarters at 3.26%

Latest Financials - Nectar Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 0.4 0.4
TTM Sales (₹ Cr.) 1,632 1,632
BVPS (₹.) 47.7 47.7
Reserves (₹ Cr.) 1,047 1,047
P/BV 0.63 0.63
PE 69.14 83.58
From the Market
52 Week Low / High (₹) 14.36 / 45.70
All Time Low / High (₹) 7.20 / 60.90
Market Cap (₹ Cr.) 675
Equity (₹ Cr.) 22.4
Face Value (₹) 1
Industry PE 48.2

Management X-Ray of Nectar Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Nectar Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales1,6381,6441,6761,6431,8762,7852,3631,5421,6681,524
Operating Expenses 1,3501,3771,4371,4191,6392,5212,1451,4401,5091,469
Manufacturing Costs100117127129145154140129147173
Material Costs1,1551,1411,1751,1541,3662,2211,8581,1561,2221,159
Employee Cost 48597876757778717275
Other Costs 48605761546969856862
Operating Profit 28826723922423626421810215955
Operating Profit Margin (%) 17.6%16.2%14.2%13.6%12.6%9.5%9.2%6.6%9.5%3.6%
Other Income 1320623664111143
Interest 1381261231171151481261127979
Depreciation 84775762646361605759
Exceptional Items 0000000-2500
Profit Before Tax 78856467635936-8534-41
Tax 1618101210116-129-18
Profit After Tax 62665455524730-7325-22
PAT Margin (%) 3.8%4.0%3.2%3.4%2.8%1.7%1.3%-4.7%1.5%-1.5%
Adjusted EPS (₹)2.83.02.42.52.32.11.3-3.31.1-1.0
Dividend Payout Ratio (%)4%3%4%2%2%2%4%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 9279589541,0071,0591,1051,1351,0611,0871,065
Share Capital 22222222222222222222
Reserves 9059369329841,0361,0821,1121,0381,0641,042
Minority Interest0000000000
Debt803861873794854802741840794685
Long Term Debt223266245164220166121128291226
Short Term Debt580595627630634636620712503459
Trade Payables440456497528539483527342377319
Others Liabilities 224236233252272315229132130100
Total Liabilities 2,3942,5102,5572,5812,7242,7042,6322,3752,3872,169

Fixed Assets

Gross Block1,3411,4511,3841,3641,4561,4901,5091,5561,5631,558
Accumulated Depreciation394518478482604666724784840896
Net Fixed Assets948934906881852825785772723662
CWIP 1229199102100100115998578
Investments 0111111111
Inventories758791836854859915975587660673
Trade Receivables377446492500612561397375447280
Cash Equivalents 1033361392121251818
Others Assets179214186229290282338516454459
Total Assets 2,3942,5102,5572,5812,7242,7042,6322,3752,3872,169

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 255144169199652392862195133
PBT 78856567635936-8534-41
Adjustment 21318517415917620718814812597
Changes in Working Capital -16-119-62-20-161-1372-39-6577
Tax Paid -20-6-9-7-13-14-9-400
Cash Flow From Investing Activity -90-60-77-18-29-26-33-291752
Capex -102-80-82-25-33-36-36-311550
Net Investments 00-10000001
Others 1221673103322
Cash Flow From Financing Activity -161-61-89-204-40-201-25211-119-186
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -138-126-123-117-115-148-126-112-79-79
Dividend Paid -2-2-3-3-1-1-1-100
Others -216637-8477-52-125125-41-106
Net Cash Flow 4233-24-41214-80
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)6.927.175.795.625.054.382.68-6.662.36-2.09
ROCE (%)12.2411.589.959.719.1210.288.241.415.792.06
Asset Turnover Ratio0.730.710.710.680.791.150.990.70.810.77
PAT to CFO Conversion(x)4.112.183.133.621.255.099.53N/A3.8N/A
Working Capital Days
Receivable Days788696104976966807876
Inventory Days153162166177149104131162118139
Payable Days1301431481621438499137107109

Nectar Lifesciences Ltd Stock News

Nectar Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Nectar Lifesciences on 28-Mar-2024 16:01 is ₹30.25.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Nectar Lifesciences stood at ₹675.2.
The latest P/E ratio of Nectar Lifesciences as of 28-Mar-2024 16:01 is 69.14.
The latest P/B ratio of Nectar Lifesciences as of 28-Mar-2024 16:01 is 0.63.
The 52-week high of Nectar Lifesciences is ₹45.70 and the 52-week low is ₹14.36.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nectar Lifesciences is ₹1,632 ( Cr.) .

About Nectar Lifesciences Ltd

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is  among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Business segments

  • APIs
  • Formulations
  • Empty hard Gelatin Capsules
  • Phytochemicals

Certifications

  • GMP (Issued by World Health Organization - COPP)
  • ISO 9001:2008 - Quality Management
  • ISO 22000:2005 - Food Safety Management
  • ISO 14001: 2004 - Environment Management Systems
  • ISO 50001: 2011 - Energy Management System
  • OHSAS 18001: 2007 - Occupational Health and Safety
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.